NCT01193595View on ClinicalTrials.gov

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Neoplasms, Malignant
Interventions
DRUG

Ombrabulin (AVE8062)

"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"

DRUG

bevacizumab

"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"

Trial Locations (4)

20132

Investigational Site Number 380002, Milan

20133

Investigational Site Number 380001, Milan

94805

Investigational Site Number 250001, Villejuif

SM2 5PT

Investigational Site Number 826001, Sutton

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY